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α-phenyl-N-tert-butyl nitrone (PBN) is a neuroprotective free radical scavenger however it 24 
has low in vivo stability and blood residence time. Aim of this study is to develop a 25 
nanoparticle formulation by using different polymeric system which enhance the blood 26 
residence time and in vivo stability of PBN and characterize in terms of particle size, zeta 27 
potential, morphology, encapsulation efficiency, in vitro release profiles. Chitosan (CS), 28 
poly(D,L-lactide-co-glycolide) (PLGA) and their poly(ethylene glycol) (PEG) block co-29 
polymers were used for comparative study. Results showed that particle sizes of CS, CS-PEG, 30 
PLGA and PLGA-PEG nanoparticles are between 142-356 nm. PLGA nanoparticles and their 31 
block-copolymers’ nanoparticle have greatly monodisperse distribution. CS and CS-PEG 32 
nanoparticles have zeta potential values between 17-40 mV related to amine groups, 33 
contrariwise PLGA and PLGA-PEG nanoparticles have negative zeta potential in the range of 34 
(-8) – (-19)  mV. Encapsulation efficiency and loading capacity for all formulations are 35 
between 12 – 54 %, 9 – 68 % respectively. PLGA-PEG nanoparticles are promising for 36 
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1. Introduction 45 
Polymeric nanoparticles have been extensively studied as particulate carriers in the 46 
pharmaceutical and medical fields, because they show promise as drug delivery systems as a 47 
result of their controlled- and sustained-release properties, subcellular size, and 48 
biocompatibility with tissue and cells [1, 2]. Biodegradable nanoparticles based on polyester 49 
polymers such as poly(D,L-lactide-co-glycolide) (PLGA) and poly(D,L-lactide) (PLA) have 50 
been widely investigated as parenteral delivery systems. Polyester polymers, approved by the 51 
Food and Drug Administration, have raised great interest due to their physicochemical and 52 
biological properties in addition to their biocompatibility and bioresorbability properties, the 53 
possibility of modulating drug release profiles by selecting the appropriate polymer is 54 
particularly interesting for the development of parenteral drug products [3].  55 
Chitosan (CS) based nanoparticles have received much attention for the delivery of drugs 56 
since this cationic polysaccharide, which is obtained by deacetylation of chitin, may be 57 
considered as non-toxic, biodegradable, and biocompatible material [4]. Chitosan 58 
nanoparticles are prepared by ionotropic gelation due to the simplicity and the lack of toxic 59 
solvents in this technique [5].  60 
The originally hydrophobic particles, after intravenous administration, will become coated by 61 
blood components (opsonins) and rapidly taken up by reticuloendothelial system (RES) [6]. 62 
Therefore, nanoparticle surfaces should be modified with hydrophilic components such as 63 
PEG. The goal of surface modification is to make the particles unrecognizable by the RES 64 
and guide it to the desired site. Particle size is also a crucial factor for prolonged circulation 65 
time in the blood stream. Generally the smaller nanoparticle with more hydrophilic surface 66 
shows less RES uptake [7]. 67 
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α-phenyl-N-tert-butyl nitrone (PBN) have emerged as a potent reactive oxygen species (ROS) 68 
scavenger,with neuroprotective efficacy and large therapeutic time window that was proven in 69 
several models of central nervous system injury, such as traumatic brain injury (TBI), stroke 70 
and intracerebral hematoma. PBN has a high degree of blood–brain barrier (BBB) penetration 71 
and a half-life in plasma of 3 hours [8, 9]. However the stability of PBN in blood is relatively 72 
low and the residence time in blood is also too short [10]. Pretreatment with a single 73 
intravenous (IV) dose of PBN (30 mg/kg 30 minutes before injury) recently has been shown 74 
to reduce cognitive deficits and lesion volume in a controlled cortical contusion model in rat. 75 
PBN has been shown to reduce infarct volume, ischemic/nitrative stress, restore microcircular 76 
patency and neuroprotective in rodent models of cerebral ischemia [8, 11, 12]. 77 
Herein we report formulation strategies to control the size, zeta potential, encapsulation 78 
efficiency and in vitro release properties of PLGA, Chitosan, PLGA-PEG and Chitosan-PEG 79 
nanoparticles. The aim of this study is to evaluate effect of polymer type on in vitro 80 
characterization of nanoparticles for further studies. To overcome low in vivo stability and 81 
short blood residence time of PBN, PEGylated and nonPEGylated polymers and also cationic 82 
natural chitosan and anionic surface charged synthetic PLGA polymers were used and 83 
discussed in detail. 84 
2. Material and Methods 85 
2.1. Materials 86 
Chitosan was commercially available as Protasan Cl 113 (MW: <150 kD, deacetylation 87 
degree: 75–90%) and was purchased from FMC Biopolymers (Norway). Chitosan-88 
poly(ethylene glycol) (CS-PEG) was previously synthesized at the University of Santiago de 89 
Compostela, Spain as described by Aktas et al. [13]. Tripolyphosphate (TPP) and PBN were 90 
supplied by Sigma Chemical Co. (USA). Ultrapure water was obtained with MilliQ 91 
equipment (Waters, USA). HPLC grade methanol was purchased from Merck (Darmstadt, 92 
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Germany). All other chemicals and reagents used were of analytical or pharmaceutical grade. 93 
PLGA (50:50; Resomer® RG 502 H, MW: 28000 Da) and  Poly[(D,L-lactide-co-glycolide)- 94 
co-PEG] diblock (RESOMER® RGP d 50105) were purchased from Boehringer Ingelheim 95 
Pharma GmbH (Ingelheim, Germany). Polyvinyl alcohol (PVA) (MW: 30000–70000 Da) was 96 
purchased from Sigma-Aldrich Co. (St. Louis, USA). Ethyl acetate was purchased from 97 
Merck KgaA (Darmstadt, Germany). Deionized water was obtained by a Millipore Milli-Q® 98 
System (Bedford, USA). All other chemicals and reagents used were of analytical or 99 
pharmaceutical grade. 100 
2.2. Preparation of drug loaded chitosan and chitosan-PEG nanoparticles 101 
CS and CS-PEG nanoparticles were prepared by the ionic gelation of TPP and CS or CS-PEG 102 
according to the procedure previously developed by P. Calvo et al. for the preparation of CS 103 
nanoparticles [14, 15]. Practically, CS nanoparticles were formed upon dropwise addition of 1 104 
mL TPP aqueous solution (0.4 mg/mL) to 1 mL of CS aqueous solution (1.75 mg/mL). 105 
Likewise, CS-PEG (1 mg/mL) nanoparticles were prepared by dropwise addition of 0.4 mL 106 
TPP aqueous solution (0.84 mg/mL) to 1 mL of each of the corresponding aqueous polymer 107 
solutions. These solutions were then stirred under magnetic stirring at medium speed (700 108 
rpm) and room temperature. PBN-loaded nanoparticles were obtained according to the same 109 
procedure, and the ratio of polymer/TPP remaining unchanged. PBN was incorporated in the 110 
polymer solution before the addition of the TPP. Two different drug concentration was chosen 111 
for loading to the nanoparticles. The resulting mixtures were broadly characterized as either a 112 
clear solution, an opalescent suspension displaying a tyndall effect (NPs), or aggregates. 113 
Nanoparticles were isolated by ultracentrifugation (10 000 rpm, 4 °C, 60 min in the presence 114 




2.3. Preparation of drug loaded PLGA and PLGA-PEG nanoparticles 118 
Nanoparticles were prepared by emulsification by homogenization-solvent evaporation 119 
(homogenization) method. Homogenization involve preparation of an organic phase 120 
consisting of polymer (PLGA or PLGA-PEG, typical concentration, 20 mg/mL) and drug 121 
(PBN,two different concentration, 1 mg/mL, 2 mg/mL) dissolved in ethyl acetate (typical 122 
volume, 10 mL). This organic phase is added to an aqueous phase containing a surfactant 123 
(PVA, typical concentration, 3%, 20 mL) to form an emulsion. This emulsion is broken down 124 
into nanodroplets by applying external energy during 2 minutes at 11 000 rpm (through a 125 
homogenizer) and these nanodroplets form nanoparticles upon evaporation of the highly 126 
volatile organic solvent. The solvent is evaporated using rotary evaporator under vacuum and 127 
37 ° C for 45 minutes leaving behind a colloidal suspension of PLGA nanoparticles in water. 128 
After the removal of ethyl acetate, nanospheres were collected by centrifugation at 13 000 129 
rpm for 20 min and lyophilized. 130 
2.4. Nanoparticle characterization 131 
Shape and morphology of nanoparticles were analysed by Scanning Electron Microscopy 132 
(SEM), using a scanning electron microscope (Nova™ NanoSEM 430, FEI, USA). Dry 133 
samples of nanospheres were mounted on carbon adhesive stubs and coated with a gold layer 134 
of appropriate thickness. The size (Z-average mean) and zeta potential of the nanoparticles 135 
were analyzed by photon correlation spectroscopy and laser doppler anemometry, 136 
respectively, in triplicate using a Zetasizer Nano Series (Nano-ZS) (Malvern Instruments, 137 
UK). Formulations were coded as presented in Table I. 138 
2.5. Determination of PBN entrapment 139 
Different methods were performed for Chitosan and PLGA nanoparticles. The amount of 140 
entrapped PBN was determined directly for chitosan and chitosan-PEG nanoparticles. 141 
Nanoparticles were resuspanded in methanol and extraction was performed using ultrasonic 142 
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bath for 30 min. Thus, nanoparticles were degraded and PBN extracted to the methanol phase. 143 
The solutions were passed through a membrane filter (pore size 0.22 µm, Millipore) before 144 
HPLC measurements. The amount of non-entrapped PBN was determined indirectly for 145 
PLGA and PLGA-PEG nanoparticles and also chitosan and chitosan-PEG nanoparticles. The 146 
supernatant containing non-entrapped PBN was separated from solid nanoparticles by 147 
ultracentrifugation by HPLC by UV detection set at 286 nm (Agilent Technologies 1200 148 
Series,USA). The mobile phase consisted of methanol:water (50:50) and the flow rate was set 149 
at 1 mL/min. Separation was achieved using a Clipeus C18 column (150mm×4.6 mm, 5 µm).  150 
PBN loading capacity (LC) of the nanoparticles and their encapsulation efficiency (AE) were 151 
calculated according to the following equations [5, 16]: 152 
 153 
Loading Capacity (%)  =                                                                          x 100   154 
 155 
 156 
Encapsulation Efficency (%)  =                                                                  x 100 157 
 158 
2.6. In vitro release studies 159 
Nanoparticles (1 mg) were resuspended in 1.5 mL of phosphate buffered saline solution 160 
(PBS) (pH 7.4) and incubated at 37 °C under light agitation. At appropriate time intervals 161 
individual samples were centrifugated and 1 mL of the supernatant was withdrawn. The 162 
amount of PBN in the release medium was determined by HPLC. The calibration curve 163 
obtained from the HPLC method was linear between 25 and 800 ng/mL (y = 0.117x – 0.044, 164 




Total PBN amount – Free PBN amount
Amount of PBN in nanoparticles
Initial amount of PBN
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3. Results 168 
3.1. Particle size, zeta potential and morphology 169 
The size (Z-average mean) and zeta potential of the nanoparticles were analyzed by photon 170 
correlation spectroscopy and laser doppler anemometry as mentioned previously. Mean 171 
nanoparticle size and zeta potential values are summarized in Table II and III. Chitosan/ 172 
Chitosan-PEG and PLGA/ PLGA-PEG nanoparticles were evaluated separately but the results 173 
will assess in discussion part in terms of preparation methods and polymer types. Particle size 174 
and zeta potential distribution of prepared nanoparticles were obtained from Zetasizer Nano 175 
Series (Figure 1, 2).   176 
To monitor the morphology of the nanoparticles scanning electron microscopy (SEM) was 177 
used. SEM pictures of drug loaded and blank nanoparticles were showed in Figure 3 - 6. As 178 
shown in SEM pictures, nanoparticles have spherical shapes and monodispers distributions. 179 
SEM pictures of chitosan nanoparticles are different from other, because when scannig 180 
process was performing nanoparticles have disintegrated because of the high energy, for this 181 
reason these photos are not including scanning process. 182 
3.2. PBN content of nanoparticles 183 
PBN content of nanoparticles was analyzed using HPLC. Direct and indirect analyses were 184 
performed for chitosan and chitosan-PEG nanoparticles, however only indirect analyses 185 
carried out for PLGA and PLGA-PEG nanoparticles because of both of them hydrophobic 186 
drug and polymer. For each formulation encapsulation efficiency (%) and drug loading 187 
capacity (%) were calculated and summarized in Table IV and V. 188 
3.3. In vitro drug release studies 189 
In vitro drug release studies was performed as mentioned in section 4.6. Prepared 190 
nanoparticles using biodegradable polymers have showed different release profiles but, both 191 
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of them have got a burst release. The reason of this burst effect adsorbed drug to the surface 192 
of nanoparticle. Release profiles were indicated in Figure 7 and 8. 193 
4. Discussion 194 
In our study, biodegradable chitosan and PLGA polymers and their modified block 195 
copolymers were used for designing PBN loaded nanoparticle drug delivery system. Effect of 196 
polymer type, PEGylation and preparation method on particle size and zeta potential of 197 
nanoparticles, encapsulation efficiency of PBN and release behaviour of PBN were 198 
investigated. PBN constitutes the parent compound of the nitrone family of spin-trapping 199 
agents commonly used to trap free radicals. Trudeau-Lame et al reported that plasma 200 
concentrations after i.v. PBN (10 mg/kg) administration declined rapidly with a terminal half-201 
life of 2.01 ± 0.35 h in male Sprague-Dawley rats and also total plasma clearance and volume 202 
of distribution at steady state averaged 12.37 ± 3.82 ml/min/kg and 1.74 ± 0.5 l/kg, 203 
respectively [17]. Whereas PBN has got considerably low in vivo stability and short blood 204 
residence time we  prepared nanocarrier systems using different biodegradable polymers 205 
modified with PEG chain. Main purpose of this study is to develop and determine optimum 206 
nanocarrier system be able to increase PBN blood residence time and concentration at the 207 
therapeutic site of action for further studies.  208 
PLGA is a hydrophobic polymer therefore nonPEGylated form of PLGA nanoparticles can be 209 
uptaken by mononuclear phagocytic system compound. PEGylated form would be provided 210 
more hydrophilic surface and also steric hindrance thus PEGylated PLGA nanoparticles 211 
present enhanced blood residence time for PBN.  212 
Through spatial and temporal controlled drug delivery, injectable nanoparticle carriers have 213 
the ability to revolutionize disease treatment. Spatially localizing the release of toxic and 214 
other potent drugs only at specific therapeutic sites can lower the overall systemic dose and 215 
damage that these drugs would otherwise produce. Temporally controlling the release of a 216 
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drug can also help decrease unwanted side effects. The overall benefit of these improvements 217 
in disease treatment would be an increase in patient compliance and quality of life. In order 218 
for a drug delivery device to achieve these desired benefits it must be present in the 219 
bloodstream long enough to reach or recognize its therapeutic site of action. However, the 220 
opsonization or removal of nanoparticulate drug carriers from the body by the mononuclear 221 
phagocytic system (MPS), also known as the RES, is a major obstacle to the realization of 222 
these goals [6]. PEG modified polymers were used to overcome these problems. 223 
Here, different biodegradable polymers were used and its effect was observed on morphology, 224 
particle size, zeta potential of nanoparticles, drug entrapment to the nanoparticles and in vitro 225 
release from the nanoparticles. Different polymer types and also PEGylation on the same 226 
polymer affected size of nanoparticle. It was observed that the size of CS-PEG NPs (142 ± 227 
13.49 nm) was smaller as compared to CS NPs (319.6 ± 19 nm) (P<0.05). This may be 228 
explained by the colloid stabilization exerted by the PEG. However particle sizes of PLGA 229 
and PLGA-PEG nanoparticles were not different statistically (P>0.5). PLGA-PEG and PLGA 230 
nanoparticles have similar sizes, because of synthetic and high purified polymers are not 231 
affected by PEGylation significantly. Compared with PLGA nanoparticles, PLGA–PEG 232 
nanoparticles showed a marked decrease in the surface charge. This could be related to a shift 233 
of the hydrodynamic phase of shear to greater distances from the nanoparticles surface. The 234 
same observations have been reported for CS and CS-PEG nanoparticles [18]. Particle size of 235 
nanoparticles is very important in terms of blood residence time. Smaller particles can be 236 
stayed longer at blood circulation.  CS-PEG NPs and PLGA-PEG NPs are not different 237 
concerning particle size however particle size distribution of PLGA-PEG NPs are more 238 
homogenious than CS-PEG NPs (P<0.5). Monodispers particle size distribution provides 239 
optimised formulations and it helps to get better pharmacokinetic results from in vivo studies. 240 
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The nanoparticles prepared in this study appeared to be spherical and rather homogeneous in 241 
size under the scanning electron microscope (Figure 3-6).  242 
Encapsulation efficiency and drug loading capacity (%) have been increased at CS, CS-PEG, 243 
PLGA and PLGA-PEG nanoparticles increasing of theoretical loaded PBN amount. It can be 244 
explained by low level of drug could not reach the saturation on polymer. Steric hindrance of 245 
PEG caused low drug loading capacity at CS-PEG nanoparticles. Compared with CS and 246 
PLGA, higher encapsulation efficiency and drug loading capacity were obtained by PLGA. 247 
Lipophilicity of PBN provides stronger interaction with hydophobic PLGA polymer. Since 248 
obtained higher encapsulation efficiency, PLGA nanoparticles can be an option for in vivo 249 
studies.  250 
For all formulations except PLGA-PEG nanoparticles, PBN release showed an initial burst 251 
release. This fast release could be relation part PBN adsorbed onto the surface of 252 
nanoparticles that would be immediately released during the initial stage. After the initial 253 
burst, PBN release profiles displayed a sustained fashion. This sustained release could result 254 
from diffusion of PBN into the polymer surface and the drug through polymer wall as well as 255 
the erosion of the polymers. In vitro release studies can be consider as a quality control test or 256 
in vitro characterization study. Obtained results showed that all formulations provide release 257 
of PBN under simulated conditions. Due to chitosan is a hydophilic biodegradable polymer 258 
release of PBN from CS NPs and CS-PEG NPs are faster than PLGA and PLGA-PEG NPs 259 
however long circulation time of PLGA-PEG nanoparticles can be provide controlled PBN 260 
release. 261 
As a conclusion, it is observed that nanoparticles can be formulated as almost spherical in 262 
shape. They have homogeneous distribution, stability, having suitable particle sizes and 263 
effective encapsulation capacity. Moreover, they exhibit initially burst release, but then 264 
controlled release following 24-hour period, so that its half life could be increased. In vivo 265 
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experiments are needed to prove the effectiveness and safety of these nanoparticule carrier 266 
system and if they could be used for neuroprotection. 267 
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Figure 1. Particle size distribution graphics of (A) CS NP, (B) CS-PEG NP, (C) PLGA NP, 340 
(D) PLGA-PEG NPS. 341 
Figure 2. Zeta potential distribution graphics of (A) CS NP, (B) CS-PEG NP, (C) PLGA NP, 342 
(D) PLGA-PEG NPS. 343 
Figure 3.  SEM pictures of blank (a) and drug loaded (b) Chitosan nanoparticles. 344 
Figure 4. SEM pictures of blank (a) and drug loaded (b) Chitosan-PEG nanoparticles. 345 
Figure 5. SEM pictures of blank (a) and drug loaded (b) PLGA nanoparticles. 346 
Figure 6. SEM pictures of blank (a) and drug loaded (b) PLGA-PEG nanoparticles. 347 
Figure 7. In vitro release profiles of PBN-loaded CS and CS-PEG nanoparticles (n=6). 348 
Figure 8. In vitro release profiles of PBN-loaded PLGA and PLGA-PEG nanoparticles (n=6). 349 
350 
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Table I. Formulation codes of nanoparticles. 351 
Formulation Code Polymer Type PBN Amount (mg) 
CS NP Chitosan HCl - 
CS1PBN NP Chitosan HCl 1 
CS2PBN NP Chitosan HCl 2 
CS-PEG NP Chitosan-PEG - 
CS-PEG3.5PBN NP Chitosan-PEG 3.5 
CS-PEG7PBN NP Chitosan-PEG 7 
PLGA NP Poly(D,L-lactide-co-glycolide) - 
PLGA10PBN NP Poly(D,L-lactide-co-glycolide) 10 
PLGA20PBN NP Poly(D,L-lactide-co-glycolide) 20 
PLGA-PEG NP Poly[(D,L-lactide-co-glycolide)- 
co-PEG] diblock 
- 
PLGA-PEG10PBN NP Poly[(D,L-lactide-co-glycolide)- 
co-PEG] diblock 
10 




  353 
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Table II. Particle size (nm), PDI and zeta potential (mV) values of CS and CS-PEG 354 











Formulation Particle Size 
(nm) 
PDI Zeta Potential 
(mV) 
CS NP 319.6 ± 18.13 0.19 +38.7 ± 7.6 
CS-PEG NP 142.4 ± 13.49 0.281 +17.5 ± 1.1 
CS1PBN NP 340 ± 19 0.3 +20.2 ± 0.9 
CS2PBN NP 356.4  ±  4.19 0.32 +18.6 ± 3.5 
CS-PEG3.5PBN NP 265.6 ± 10.54 0.434 +25.9 ± 0.44 
CS-PEG7PBN NP 208.8 ± 1.153 0.424 +23.45 ± 0.49 
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Table III. Particle size (nm), PDI and zeta potential (mV) values of PLGA and PLGA-PEG 366 
nanoparticles containing different concentrations of PBN. 367 
 368 
 369 
Formulation Particle size 
(nm) 
PDI Zeta Potential 
(mV) 
PLGA NP 269.6 ± 6.42 0.09 -18.4 ± 2.86 
PLGA-PEG NP 271.1 ± 4.88 0.051 -14.4 ± 0.53 
PLGA10PBN NP 
(before lyophilization) 
279.06 ± 5.71 0.063 -7.9 ± 3.2 
PLGA20PBN NP 
(before lyophilization) 
285.6 ± 3.93 0.075 -15.4 ± 3.8 
PLGA10PBN NP 
(after lyophilization) 
318.4 ± 10.87 0.191 -14.7 ± 0.36 
PLGA20PBN NP 
(after lyophilization) 
303.1 ± 15.54 0.197 -16.3 ± 0.3 
PLGA-PEG10PBN NP 
(before lyophilization) 
278.2 ± 2.177 0.07 -12.9 ± 0.34 
PLGA-PEG20 PBN NP 
(before lyophilization) 
290.0 ± 2.1 0.09 -11.9 ± 0.47 
PLGA-PEG10PBN NP 
(after lyophilization) 
293.6 ± 6.03 0.11 -13.3 ± 1.03 
PLGA-PEG20PBN NP 
(after lyophilization) 
301.8 ± 2.82 0.098 -14.0 ± 0.7 
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 370 











CS NP - - - 
CS-PEG NP - - - 
CS1PBN NP 32.67 ± 2.3 326.7 16.5 ± 0.2 
CS2PBN NP 44.65 ± 2.8 1106.87 55.9 ± 0.3 
CS-PEG3.5PBN NP 53.26 ± 1.8 1065.25 29.91 ± 0.11 
CS-PEG7PBN NP 24 ± 3.3 1680 47.19 ± 0.35 
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Table V. Encapsulation efficiency and drug loading capacity of PBN-loaded PLGA and 375 








PLGA NP - - - 
PLGA-PEG NP - - - 
PLGA10PBN NP 
 
52.3 ± 2.4 5.23 34.36 ± 0.28 
PLGA20PBN NP 
 
54 ± 3.1 10.815 68.40 ± 0.29 
PLGA-PEG10PBN NP 12.7 ± 1.6 1.27 9.26 ± 0.22 
PLGA-PEG20PBN NP 
 
21.21 ± 2.2 4.242 29.24 ± 0.24 
 377 










Figure 1. Particle size distribution graphics of (A) CS NP, (B) CS-PEG NP, (C) PLGA NP, 387 
















Figure 2. Zeta potential distribution graphics of (A) CS NP, (B) CS-PEG NP, (C) PLGA NP, 404 
(D) PLGA-PEG NPS. 405 
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  459 
Figure 8. In vitro release profiles of PBN-loaded PLGA and PLGA-PEG nanoparticles (n=6). 460 
